Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
Sign Up to like & getrecommendations! Published in 2023 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000871
Abstract: The gut microbiome acts as a tumor-extrinsic regulator of responses to immune-checkpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 receptors. Primary resistance to anti-PD-1 ICI can be reversed via responder-derived fecal microbiota transplant (FMT) in patients… read more here.
Keywords: fecal microbiota; refractory melanoma; responder;
Antigen-Loaded Extracellular Vesicles Induce Responsiveness to Anti–PD-1 and Anti–PD-L1 Treatment in a Checkpoint Refractory Melanoma Model
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-22-0540
Abstract: In mice with checkpoint-refractory melanoma, antigen-loaded EVs induce antitumor immune responses. Prophylactic immunization with EVs sensitizes tumors to anti–PD-L1 and leads to prolonged survival, indicating potential use of EVs against checkpoint-refractory cancers. read more here.
Keywords: checkpoint refractory; antigen loaded; refractory melanoma;
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.897991
Abstract: Section Head Clinical/translational cancer immunotherapy Background The goal of this study was to estimate the objective response rate for utomilumab in adults with immune checkpoint inhibitor (ICI)-refractory melanoma and non–small-cell lung cancer (NSCLC). Methods Utomilumab… read more here.
Keywords: cell; checkpoint inhibitor; immune checkpoint; melanoma ... See more keywords